Biomarkers in Inflammatory Rheumatic Diseases Diagnosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorUniversidade Nova de Lisboa
About this trial
Ankylosing spondylitis (AS), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are three diseases where early diagnosis remains a major challenge. However, early diagnosis is the main determinant for a better prognosis. In the early stage, symptoms may be nonspecific and often difficult to establish a differential diagnosis between rheumatic diseases and other diseases, namely infectious and cancer diseases.
Eligibility criteria
Qualifiers
Diagnosis of AS, RA, SLE according the mentioned criteria;
Ability to provide informed consent;
If entering the study on NSAIDs, tramadol, combination of paracetamol and codeine or hydrocodone, and/or non-opioid analgesics, subject must be on stable dose(s) for at least 14 days prior to the screening visit;
If entering the study on oral corticosteroids, subject must be on a stable dose of prednisone (≤ 10 mg/day), or oral corticosteroid equivalents, for at least 14 days prior to the screening visit;
Disqualifiers
Current pregnancy or breastfeeding;
Prior exposure to any biologic therapy;
Intra-articular joint or tendon sheaths injections, spinal/paraspinal injection(s), or parenteral administration of corticosteroids within 28 days prior to the Baseline Visit. Inhaled or topical corticosteroids are allowed;
Receipt of any live vaccine within 4 weeks prior to the screening visit;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
134 Participants
are grouped into 4 trial groupsSponsors and collaborators
Universidade Nova de Lisboa
Lead sponsor
Centro Hospitalar Lisboa Ocidental
Collaborator
Source ClinicalTrials.gov